COMMUNIQUÉS West-GlobeNewswire

Flyte Named Official Air Travel Partner of the 34th Annual Hamptons International Film Festival
28/09/2026
Partnership Expands Flyte’s Growing Presence Across Entertainment, Fashion, Hospitality, Sports and Premium Destination Travel 2026 Flyte Breakthrough Awards will Honor Anthony Ippolito, Star of Amazon MGM Studios’ “I [...]
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
28/09/2026
MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a numerical improvement in liver fat LA JOLLA, Calif., Sept. 28, 2026 [...]
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
28/09/2026
Acquisition diversifies durable cash flows and advances Zymeworks’ strategy to build a productive R&D company with a growing portfolio of revenue-generating assets YUPELRI ® expected to contribute immediately [...]
Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA
28/09/2026
REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis , Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with [...]
Lift Therapeutics Appoints Eva Ehrnrooth as Executive Head of Clinical Development and Adds Chau Khuong to Board of Directors
28/09/2026
London, September 28, 2026 – Lift Therapeutics (‘Lift’ or ‘the Company’) today announced the appointment of Eva Ehrnrooth, MD, PhD, as Executive Head of Clinical Development and Chau Khuong to its Board of Directors. Dr [...]
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
28/09/2026
New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience FDA removal of the prior drug exposure limit provides greater dosing flexibility in future [...]
U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
28/09/2026
NDA submission completed following positive Phase 3 SELVA results; potential U.S. commercial launch in the first half of 2027, if approved QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and [...]
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
28/09/2026
BARDA partnership accelerates development of SCY-247 as a potential therapy for the treatment and prevention of serious invasive fungal infections, addressing a critical public health need Non-dilutive funding for SCY- [...]
Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
28/09/2026
Dr. Houvras brings over two decades of executive leadership across premier industry and academic research institutions in clinical development, translational medicine and immuno-oncology WALTHAM, Mass., Sept. 28, 2026 ( [...]
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
28/09/2026
- Stable or increased weight was twice as common among pancreatic cancer patients in the atebimetinib + mGnP study, compared to those in a benchmark study - - Patients with stable or increased weight at three months had [...]
Pharmazz Completes Enrollment in 160-Patient Phase 4 Trial of Sovateltide in Acute Ischemic Stroke
28/09/2026
Enrollment completed in the double-blind, placebo-controlled Phase 4 study ( NCT05955326 ) of sovateltide (Tycamzzi®), with final study data expected in Q1 2027 Five sovateltide abstracts accepted at World Stroke [...]
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate
28/09/2026
– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors – NEW HAVEN, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: [...]
Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine
28/09/2026
– Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits – Independent Cleveland Clinic cardio-oncology [...]
BrewDog Builds Momentum for Next Growth Chapter with Expanded Senior Leadership Team
28/09/2026
New appointments strengthen marketing, hospitality, category, and international commercial leadership as BrewDog advances long-term growth under Tilray Brands ELLON, Scotland and LONDON, Sept. 28, 2026 (GLOBE NEWSWIRE [...]
A New International Medical Approach Aimed at Reversing Diabetes has Officially Launched in Shenzhen, China
28/09/2026
SHENZHEN, China, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Recently in Shenzhen, China, the Center for Integrative Medicine for Chronic Diseases and the Center for Natural Diabetes Therapy at Shenzhen Hengsheng Hospital—a [...]
Thermo Fisher Scientific and Evosep Enter Reseller Agreement for Evosep Eno
28/09/2026
Thermo Fisher Scientific to offer the Evosep Eno separation platform to customers, expanding access to standardized, high-throughput proteomics workflows SINGAPORE, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Evosep™, a global [...]
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition
28/09/2026
NANJING, China, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that opamtistomig (LBL-024), the Company’s proprietary PD‑L1/4‑ [...]
Bavarian Nordic – Transactions in Connection with Share Buy-Back Program
28/09/2026
COPENHAGEN, Denmark, September 28, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase shares for an [...]
Unlocking the Growth - Invitation to BioPorto’s investor meeting on October 7
28/09/2026
September 28, 2026 News release Unlocking the Growth - Invitation to BioPorto’s investor meeting on October 7 As BioPorto continues to advance its commercial strategy and capitalize on emerging clinical opportunities, [...]

Pages